N/A
N=700
Extended Spectrum Betalactamase Producing Bacteria; Epidemiology and Treatment in Non-hospitalized Patients
Urinary Tract Infection · Infection Due to ESBL Bacteria · Environmental Contamination of ESBL
Bottom Line
View on ClinicalTrials.gov: NCT01838213 ↗Enrolled (actual)
700
Serious AEs
0.0%
Results posted
Nov 2015
Primary outcome: Primary: Treatment Failure — 23; 101 Treatment success
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Vestre Viken Hospital Trust
- Primary completion
- Dec 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Treatment Failure |
23; 101 | — |
| SECONDARY Subjective Outcome |
— | — |
Summary
This project aims at investigating the duration of human fecal carriage of bacteria harboring plasmid-borne resistance genes expressing Extended Spectrum beta-lactamases (ESBL), risk factors for infections with such bacteria and persistence, mobility and spread of ESBL in the environment and within households. It also aims to compare different methods of detecting ESBL carriage and treat patients with urinary tract infection caused by these bacteria.
Eligibility Criteria
Inclusion Criteria
- Patients >=18 of age with a urine culture yielding E. coli or K. pneumoniae >10.000 colony forming units/mL.
Exclusion Criteria
- Patients who have lived in Norway for 24 hours during the past 31 days.
Data sourced from ClinicalTrials.gov (NCT01838213). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.